Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free XERS Stock Alerts

Xeris Biopharma (XERS) Short Interest Ratio & Short Volume

Xeris Biopharma logo
$5.99 -0.08 (-1.29%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Xeris Biopharma Short Interest Overview

As of May 15, 2026, Xeris Biopharma (XERS) had a short interest of 12.36 million shares sold short, representing 7.66% of the public float. This marks a -22.21% decrease in short interest since the prior report. The short interest ratio (days to cover) is 5.8, meaning it would take 5.8 days of the average trading volume of 1.72 million shares to cover all short positions.

Current Short Interest
12,364,664 shares
Previous Short Interest
15,894,656 shares
Change Vs. Previous Month
-22.21%
Dollar Volume Sold Short
$77.16 million
Short Interest Ratio
5.8 Days to Cover
Last Record Date
May 15, 2026
Outstanding Shares
172,640,000 shares
Short Percent of Float
7.66%
Today's Trading Volume
1,406,991 shares
Average Trading Volume
1,715,969 shares
Today's Volume Vs. Average
82%
Short Selling Xeris Biopharma?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Xeris Biopharma and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

XERS Short Interest Over Time

XERS Days to Cover Over Time

XERS Percentage of Float Shorted Over Time

Xeris Biopharma Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/15/202612,364,664 shares $77.16 million -22.2%7.7%5.8 $6.24
4/30/202615,894,656 shares $97.43 million +1.0%9.6%12.68 $6.13
4/15/202615,738,746 shares $97.58 million -4.1%9.8%11.01 $6.20
3/31/202616,412,903 shares $95.19 million +1.2%10.2%8.94 $5.80
3/13/202616,223,073 shares $88.58 million -4.7%9.9%6.77 $5.46
2/27/202617,015,319 shares $104.13 million -2.1%10.3%7.47 $6.12
2/13/202617,385,964 shares $118.57 million +2.3%11.0%13.89 $6.82
1/30/202616,996,095 shares $125.09 million +0.7%10.7%11.51 $7.36
1/15/202616,883,379 shares $125.11 million +2.2%10.7%6.04 $7.41
12/31/202516,522,754 shares $129.70 million +7.1%10.4%7.75 $7.85
12/15/202515,434,811 shares $108.82 million -3.4%9.7%6.93 $7.05
11/28/202515,974,039 shares $114.77 million +1.5%10.1%8.98 $7.19
11/14/202515,746,194 shares $113.06 million -10.7%9.9%4.01 $7.18
10/31/202517,626,897 shares $170.98 million -1.3%11.1%8.61 $9.70
10/15/202517,850,000 shares $165.47 million +2.4%11.6%7.1 $9.27
9/30/202517,440,000 shares $141.96 million +7.4%N/A7.3 $8.14
9/15/202516,240,000 shares $119.53 million +10.4%N/A6.7 $7.36
8/31/202514,710,000 shares $115.18 million +10.2%9.7%6.2 $7.83
8/15/202513,350,000 shares $102.53 million -26.7%N/A5.4 $7.68
7/31/202518,220,000 shares $92.74 million -6.8%12.1%7.4 $5.09
7/15/202519,550,000 shares $103.42 million +164.6%N/A9.1 $5.29
6/30/20257,390,000 shares $34.51 million -58.8%5.1%5.8 $4.67
6/15/202517,940,000 shares $78.04 million +1.9%12.3%6.9 $4.35
5/31/202517,600,000 shares $86.77 million -1.1%12.4%5.8 $4.93
5/15/202517,800,000 shares $85.26 million +3.3%12.5%5.8 $4.79
4/30/202517,230,000 shares $78.74 million -9.6%N/A5.6 $4.57
4/15/202519,050,000 shares $83.44 million +11.8%13.4%6.5 $4.38
3/31/202517,040,000 shares $93.55 million +52.0%12.0%6.1 $5.49
3/15/202511,210,000 shares $54.03 million +5.5%7.9%4.8 $4.82
2/28/202510,630,000 shares $40.71 million +3.5%7.5%5.5 $3.83
2/15/202510,270,000 shares $36.87 million -2.1%7.2%6.3 $3.59
1/31/202510,490,000 shares $37.34 million +1.3%N/A6.2 $3.56
1/15/202510,360,000 shares $33.57 million +1.7%N/A6.3 $3.24
12/31/202410,190,000 shares $34.54 million +7.0%N/A6.4 $3.39
12/15/20249,520,000 shares $31.23 million -3.9%N/A6.1 $3.28
11/30/20249,910,000 shares $32.50 million -2.4%N/A6.1 $3.28
11/15/202410,150,000 shares $29.64 million -10.7%N/A6.4 $2.92
10/31/202411,370,000 shares $36.61 million -1.7%N/A7.2 $3.22
10/15/202411,570,000 shares $34.94 million +4.3%N/A7.7 $3.02
9/30/202411,090,000 shares $31.61 million +0.8%N/A7.2 $2.85
Before you buy SpaceX shares, consider this alternative approach (Ad)

SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel

Discover the overlooked SpaceX IPO strategy before the June listing
9/15/202411,000,000 shares $31.68 million +2.7%N/A7.1 $2.88
8/31/202410,710,000 shares $30.10 million -0.9%N/A7.6 $2.81
8/15/202410,810,000 shares $28.32 million -3.7%N/A7.5 $2.62
7/31/202411,220,000 shares $27.83 million -1.7%N/A7.9 $2.48
7/15/202411,410,000 shares $28.30 million +3.7%N/A8.7 $2.48
6/30/202411,000,000 shares $24.75 million -0.8%N/A8.2 $2.25
6/15/202411,088,000 shares $24.39 million -2.1%N/A7.9 $2.20
5/31/202411,330,000 shares $25.55 million +5.0%N/A7.3 $2.26
5/15/202410,790,000 shares $21.36 million +11.9%N/A6.4 $1.98
4/30/20249,640,000 shares $16.87 million +7.8%N/A5.2 $1.75
4/15/20248,940,000 shares $16.54 million -0.5%N/A4.8 $1.85
3/31/20248,980,000 shares $19.85 million -2.8%N/A4 $2.21
3/15/20249,240,000 shares $20.61 million -4.2%N/A4 $2.23
2/29/20249,640,000 shares $29.64 million +2.3%N/A4.2 $3.08
2/15/20249,420,000 shares $30.24 million +0.2%N/A4.6 $3.21
1/31/20249,400,000 shares $23.12 million -9.7%N/A4.7 $2.46
1/15/202410,410,000 shares $28.84 million +8.3%N/A5.5 $2.77
12/31/20239,610,000 shares $22.58 million +18.4%N/A6.6 $2.35
12/15/20238,120,000 shares $16.40 million -1.2%N/A6.2 $2.02
11/30/20238,220,000 shares $15.29 million -8.2%N/A7 $1.86
11/15/20238,950,000 shares $13.16 million +14.9%N/A8.1 $1.47
10/31/20237,790,000 shares $14.26 million +2.4%N/A8.4 $1.83
10/15/20237,610,000 shares $12.02 million -4.0%N/A8 $1.58
9/30/20237,930,000 shares $14.75 million +0.6%N/A8.4 $1.86
9/15/20237,880,000 shares $15.76 million +6.2%N/A7.5 $2.00
8/31/20237,420,000 shares $16.84 million -12.9%N/A6.9 $2.27
8/15/20238,520,000 shares $19.00 million +2.7%N/A7.8 $2.23
7/31/20238,300,000 shares $21.66 million -2.6%N/A7.1 $2.61
7/15/20238,520,000 shares $21.64 million +0.4%N/A7.2 $2.54
6/30/20238,490,000 shares $22.24 million -5.0%N/A6.5 $2.62
6/15/20238,940,000 shares $24.23 million +13.6%N/A6.7 $2.71
5/31/20237,870,000 shares $20.15 million -5.5%N/A6.2 $2.56
5/15/20238,330,000 shares $23.66 million -1.9%N/A6.3 $2.84
4/30/20238,490,000 shares $19.19 million +6.3%N/A6.9 $2.26
4/15/20237,990,000 shares $17.34 million +2.0%N/A7 $2.17
3/31/20237,830,000 shares $12.76 million -5.4%N/A6.7 $1.63
3/15/20238,280,000 shares $10.76 million +20.9%N/A7.6 $1.30
2/28/20236,850,000 shares $9.45 million +13.4%N/A6.9 $1.38
2/15/20236,040,000 shares $7.61 million -6.9%N/A6.8 $1.26
1/31/20236,490,000 shares $8.05 million +9.1%N/A7.7 $1.24
1/15/20235,950,000 shares $7.62 million +1.9%N/A6.8 $1.28
12/30/20225,840,000 shares $7.77 million +2.5%N/A6.5 $1.33
12/15/20225,700,000 shares $7.64 million -0.7%N/A7.3 $1.34
11/30/20225,740,000 shares $8.61 million -9.5%N/A7 $1.50
11/15/20226,340,000 shares $8.81 million +0.8%N/A7.7 $1.39
10/31/20226,290,000 shares $10.06 million +0.8%N/A7.6 $1.60
10/15/20226,240,000 shares $7.61 million -5.5%N/A7.2 $1.22
9/30/20226,600,000 shares $10.30 million -21.6%N/A8 $1.56
9/15/20228,420,000 shares $15.07 million -8.1%N/A8 $1.79
8/31/20229,160,000 shares $15.30 million -4.8%N/A8.3 $1.67
The REAL Reason Trump is Invading Iran (Ad)

For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel

Click here to find out what it is.
8/15/20229,620,000 shares $18.18 million -7.1%N/A7.5 $1.89
7/31/202210,350,000 shares $14.70 million +4.9%N/A6.1 $1.42
7/15/20229,870,000 shares $14.11 million -3.3%N/A5.5 $1.43
6/30/202210,210,000 shares $15.72 million +64.7%N/A5.6 $1.54
6/15/20226,200,000 shares $10.91 million -8.3%N/A3.3 $1.76
5/31/20226,760,000 shares $14.94 million +9.0%N/A3.7 $2.21
5/15/20226,200,000 shares $10.60 million +14.6%N/A3.4 $1.71
4/30/20225,410,000 shares $13.20 million +20.2%N/A3.3 $2.44
4/15/20224,500,000 shares $11.03 million +12.8%N/A2.6 $2.45
3/31/20223,990,000 shares $10.21 million -23.4%N/A2.1 $2.56
3/15/20225,210,000 shares $13.91 million -1.7%N/A1.7 $2.67
2/28/20225,300,000 shares $12.61 million -17.3%N/A1.8 $2.38
2/15/20226,410,000 shares $16.47 million -3.5%N/A2.1 $2.57
1/31/20226,640,000 shares $14.01 million +41.6%N/A2.1 $2.11
1/15/20224,690,000 shares $10.41 million +27.5%N/A1.5 $2.22
12/31/20213,680,000 shares $10.78 million +4.3%N/A0 $2.93
12/15/20213,530,000 shares $8.01 million +16.1%N/A1.9 $2.27
11/30/20213,040,000 shares $6.35 million -30.9%N/A1.8 $2.09
11/15/20214,400,000 shares $10.91 million +14.6%N/A2.4 $2.48
10/29/20213,840,000 shares $7.14 million +13.6%N/A1.1 $1.86
10/15/20213,380,000 shares $6.76 million -17.2%N/A1 $2.00
9/30/20214,080,000 shares $10.00 million -5.1%N/A1.2 $2.45
9/15/20214,300,000 shares $10.97 million -12.1%6.6%1.2 $2.55
8/31/20214,890,000 shares $13.50 million +9.9%7.6%1.2 $2.76
8/13/20214,450,000 shares $10.32 million -17.3%6.9%1 $2.32
7/30/20215,380,000 shares $16.52 million +0.6%8.2%1.8 $3.07
7/15/20215,350,000 shares $18.89 million -60.1%8.3%1.8 $3.53
6/30/202113,400,000 shares $54.54 million -13.9%20.7%4.4 $4.07
6/15/202115,570,000 shares $64.46 million +1.8%24.0%5.4 $4.14

XERS Short Interest - Frequently Asked Questions

Short interest is the volume of Xeris Biopharma shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 12,364,664 shares of XERS short. 7.66% of Xeris Biopharma's shares are currently sold short. Learn More on Xeris Biopharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. XERS shares currently have a short interest ratio of 5.8. Learn More on Xeris Biopharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.66% of Xeris Biopharma's floating shares are currently sold short.

Xeris Biopharma saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 12,364,664 shares, a decline of 22.2% from the previous total of 15,894,656 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

7.66% of Xeris Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Xeris Biopharma: MANE (4.91%), NewAmsterdam Pharma Company N.V. (7.00%), Travere Therapeutics, Inc. (15.76%), Kiniksa Pharmaceuticals International, plc (8.59%), Amneal Pharmaceuticals, Inc. (3.02%), Crinetics Pharmaceuticals, Inc. (12.99%), Catalyst Pharmaceuticals, Inc. (6.30%), Twist Bioscience Corporation (27.47%), Oruka Therapeutics, Inc. (13.55%), ACADIA Pharmaceuticals Inc. (9.04%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($80.71 billion), Invesco QQQ ($47.96 billion), iShares Russell 2000 ETF ($22.13 billion), Western Digital Corporation ($14.35 billion), Sandisk Corporation ($12.86 billion), Salesforce Inc. ($10.89 billion), Nebius Group N.V. ($9.92 billion), SPDR S&P Biotech ETF ($9.72 billion), Lumentum Holdings Inc. ($8.89 billion), and iShares 20+ Year Treasury Bond ETF ($8.18 billion). View all of the most shorted stocks.

Short selling XERS is an investing strategy that aims to generate trading profit from Xeris Biopharma as its price is falling. XERS shares are trading down $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Xeris Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of XERS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XERS, twice per month. The most recent reporting period available is May, 15 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like XERS:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:XERS) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel